446 related articles for article (PubMed ID: 26337211)
1. Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies.
Reddy SM; Vergo MT; Paice JA; Kwon N; Helenowski IB; Benson AB; Mulcahy MF; Nimeiri HS; Harden RN
Clin Colorectal Cancer; 2016 Mar; 15(1):37-46. PubMed ID: 26337211
[TBL] [Abstract][Full Text] [Related]
2. Electroclinical biomarkers of early peripheral neurotoxicity from oxaliplatin.
McHugh JC; Tryfonopoulos D; Fennelly D; Crown J; Connolly S
Eur J Cancer Care (Engl); 2012 Nov; 21(6):782-9. PubMed ID: 22594346
[TBL] [Abstract][Full Text] [Related]
3. Is quantitative sensory testing helpful in the management of oxaliplatin neuropathy? a two-year clinical study.
Delmotte JB; Beaussier H; Auzeil N; Massicot F; Laprévote O; Raymond E; Coudoré F
Cancer Treat Res Commun; 2018; 17():31-36. PubMed ID: 30343217
[TBL] [Abstract][Full Text] [Related]
4. Oxaliplatin-Induced Neuropathy: A Long-Term Clinical and Neurophysiologic Follow-Up Study.
Kokotis P; Schmelz M; Kostouros E; Karandreas N; Dimopoulos MA
Clin Colorectal Cancer; 2016 Sep; 15(3):e133-40. PubMed ID: 27038553
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer.
Griffith KA; Zhu S; Johantgen M; Kessler MD; Renn C; Beutler AS; Kanwar R; Ambulos N; Cavaletti G; Bruna J; Briani C; Argyriou AA; Kalofonos HP; Yerges-Armstrong LM; Dorsey SG
J Pain Symptom Manage; 2017 Nov; 54(5):701-706.e1. PubMed ID: 28743660
[TBL] [Abstract][Full Text] [Related]
8. Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study.
Attal N; Bouhassira D; Gautron M; Vaillant JN; Mitry E; Lepère C; Rougier P; Guirimand F
Pain; 2009 Aug; 144(3):245-252. PubMed ID: 19457614
[TBL] [Abstract][Full Text] [Related]
9. Quantification of Chronic Oxaliplatin-Induced Hypesthesia in Two Areas of the Hand.
Andriamamonjy M; Delmotte JB; Savinelli F; Beaussier H; Coudoré F
J Clin Neurophysiol; 2017 Mar; 34(2):126-131. PubMed ID: 27749615
[TBL] [Abstract][Full Text] [Related]
10. Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study.
El-Fatatry BM; Ibrahim OM; Hussien FZ; Mostafa TM
Int J Colorectal Dis; 2018 Dec; 33(12):1675-1683. PubMed ID: 29931409
[TBL] [Abstract][Full Text] [Related]
11. Impact of oxaliplatin-induced neuropathy: a patient perspective.
Bennett BK; Park SB; Lin CS; Friedlander ML; Kiernan MC; Goldstein D
Support Care Cancer; 2012 Nov; 20(11):2959-67. PubMed ID: 22426503
[TBL] [Abstract][Full Text] [Related]
12. Late effects of oxaliplatin-induced peripheral neuropathy (LEON)--cross-sectional cohort study of patients with colorectal cancer surviving at least 2 years.
Padman S; Lee J; Kumar R; Slee M; Hakendorf P; Richards A; Koczwara B; Kichenadasse G; Sukumaran S; Roy A; Vatandoust S; Karapetis CS
Support Care Cancer; 2015 Mar; 23(3):861-9. PubMed ID: 25223350
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy.
Sereno M; Gutiérrez-Gutiérrez G; Rubio JM; Apellániz-Ruiz M; Sánchez-Barroso L; Casado E; Falagan S; López-Gómez M; Merino M; Gómez-Raposo C; Rodriguez-Salas N; Tébar FZ; Rodríguez-Antona C
BMC Cancer; 2017 Jan; 17(1):63. PubMed ID: 28103821
[TBL] [Abstract][Full Text] [Related]
14. Clinical management of oxaliplatin-associated neurotoxicity.
Grothey A
Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S38-46. PubMed ID: 15871765
[TBL] [Abstract][Full Text] [Related]
15. Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).
Pachman DR; Qin R; Seisler DK; Smith EM; Beutler AS; Ta LE; Lafky JM; Wagner-Johnston ND; Ruddy KJ; Dakhil S; Staff NP; Grothey A; Loprinzi CL
J Clin Oncol; 2015 Oct; 33(30):3416-22. PubMed ID: 26282635
[TBL] [Abstract][Full Text] [Related]
16. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer.
Argyriou AA; Cavaletti G; Briani C; Velasco R; Bruna J; Campagnolo M; Alberti P; Bergamo F; Cortinovis D; Cazzaniga M; Santos C; Papadimitriou K; Kalofonos HP
Cancer; 2013 Jan; 119(2):438-44. PubMed ID: 22786764
[TBL] [Abstract][Full Text] [Related]
17. Nerve excitability assessment in chemotherapy-induced neurotoxicity.
Park SB; Lin CS; Kiernan MC
J Vis Exp; 2012 Apr; (62):. PubMed ID: 22565594
[TBL] [Abstract][Full Text] [Related]
18. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.
Park SB; Goldstein D; Lin CS; Krishnan AV; Friedlander ML; Kiernan MC
J Clin Oncol; 2009 Mar; 27(8):1243-9. PubMed ID: 19164207
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin-induced peripheral neuropathy's effects on health-related quality of life of colorectal cancer survivors.
Tofthagen C; Donovan KA; Morgan MA; Shibata D; Yeh Y
Support Care Cancer; 2013 Dec; 21(12):3307-13. PubMed ID: 23903798
[TBL] [Abstract][Full Text] [Related]
20. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7.
Grothey A; Nikcevich DA; Sloan JA; Kugler JW; Silberstein PT; Dentchev T; Wender DB; Novotny PJ; Chitaley U; Alberts SR; Loprinzi CL
J Clin Oncol; 2011 Feb; 29(4):421-7. PubMed ID: 21189381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
